title: Immunotherapy for non-small cell lung cancer: are we on the cusp of a new era?
abstract: In this editorial, we highlight the exciting advances in immunotherapy for the treatment of non-small cell lung cancer, with nivolumab being the first immunotherapeutic agent to be approved by the US FDA for the treatment of squamous lung cancer and several other promising immune checkpoint inhibitors currently being evaluated in clinical trials. The next step is to understand the mechanisms of resistance and develop rational combinations in an attempt to further improve the responses and survival in lung cancer.
authors.affiliation: Department of Medicine, Division of Oncology, Washington University School of Medicine, St. Louis, MO, USA.
authors.forename: Saiama N
authors.initials: SN
authors.lastname: Waqar
authors.forename: Daniel
authors.initials: D
authors.lastname: Morgensztern
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000276:immunology / Q000628:therapy*; D002986:Clinical Trials as Topic; D017277:Drug Approval; D019008:Drug Resistance, Neoplasm; D006801:Humans; D007167:Immunotherapy; D008175:Lung Neoplasms / Q000276:immunology / Q000628:therapy*; D000077594:Nivolumab; D014481:United States
chemical_list: D000911:Antibodies, Monoclonal; D000077594:Nivolumab
keywords: PD-1; PDL-1; immunotherapy; nivolumab; non-small cell lung cancer